Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Update on overall survival in ARCHES trial

Andrew J. Amstrong, MD, Duke Cancer Institute, Durham, NC, gives an update on the overall survival results for the ARCHES trial (NCT02677896), which looked at enzalutamide, an androgen receptor (AR) inhibitor, in combination with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer. The updated overall survival results are highly promising, with a greater probability of delaying the symptomatic and radiographic progression of disease. Prof. Armstrong compares these results with those of ENZAMET (NCT02446405) for this patient type. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Dr Armstrong reports research support (to Duke) from the NIH/NCI, PCF/Movember, DOD, Astellas, Pfizer, Bayer, Janssen, Dendreon, Genentech/Roche, BMS, AstraZeneca, Merck, Constellation, Beigene, Forma, Celgene, Amgen.

Dr Armstrong reports consulting or advising relationships with Astellas, Pfizer, Bayer, Janssen, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Clovis, Exact Sciences